Vaxxinity Statistics
Share Statistics
Vaxxinity has 126.78M shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 126.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 55.62M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 4.22M, so 3.33% of the outstanding shares have been sold short.
| Short Interest | 4.22M |
| Short % of Shares Out | 3.33% |
| Short % of Float | 7.59% |
| Short Ratio (days to cover) | 13.97 |
Valuation Ratios
The PE ratio is -1.89 and the forward PE ratio is null.
| PE Ratio | -1.89 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.01 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Vaxxinity Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.89 |
| Quick Ratio | 1.89 |
| Debt / Equity | 1.13 |
| Total Debt / Capitalization | 53.08 |
| Cash Flow / Debt | -3.77 |
| Interest Coverage | -83.74 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -998.84 |
| Employee Count | 57 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -56.93K |
| Effective Tax Rate | 1 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.07, so Vaxxinity 's price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.1 |
| Relative Strength Index (RSI) | 47.9 |
| Average Volume (20 Days) | 29.41K |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.23M |
| Operating Income | -58.28M |
| Net Income | -56.93K |
| EBITDA | -56.05K |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.45 |
Balance Sheet
The company has 5.04M in cash and 15.17M in debt, giving a net cash position of -10.13M.
| Cash & Cash Equivalents | 5.04M |
| Total Debt | 15.17M |
| Net Cash | -10.13M |
| Retained Earnings | -361.64M |
| Total Assets | 44.31M |
| Working Capital | 15.63M |
Cash Flow
In the last 12 months, operating cash flow was -57.24M and capital expenditures -803.00K, giving a free cash flow of -58.04M.
| Operating Cash Flow | -57.24M |
| Capital Expenditures | -803.00K |
| Free Cash Flow | -58.04M |
| FCF Per Share | -458.79 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VAXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | -91558.87% |
Analyst Forecast
Currently there are no analyst rating for VAXX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -15.11 |
| Piotroski F-Score | 0 |